Xeris Pharmaceuticals ( (XERS) ) has released its Q3 earnings. Here is a breakdown of the information Xeris Pharmaceuticals presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Xeris Biopharma Holdings, Inc. is a rapidly expanding biopharmaceutical company dedicated to enhancing patient lives through the development and commercialization of innovative therapeutic products. The company operates in the healthcare sector, with a focus on treatments for conditions such as endogenous Cushing’s syndrome, severe hypoglycemia, and primary periodic paralysis.
In its latest earnings report for the third quarter of 2025, Xeris Biopharma announced a significant increase in total product revenue, which rose by 40% year-over-year to $74 million. This growth was primarily driven by the impressive performance of Recorlev®, which saw its revenue more than double compared to the previous year. The company has updated its full-year revenue guidance to a range of $285-$290 million, reflecting continued strong demand for its products.
Key financial highlights from the report include a notable 109% year-over-year increase in Recorlev® revenue, reaching $37 million. Gvoke® also contributed positively with a 10% increase in revenue, while Keveyis® experienced a slight decline. The company’s cost of goods sold decreased by 19%, and research and development expenses rose by 27%, indicating ongoing investment in future growth. Xeris reported a net income of $0.6 million for the quarter, a significant improvement from the net loss of $15.7 million in the same period last year.
The company’s strategic focus on expanding its product portfolio and enhancing its operational efficiency has resulted in a robust adjusted EBITDA of $17.4 million for the quarter. Xeris continues to invest in its pipeline, including the development of XP-8121, a promising treatment for hypothyroidism, and other early-stage programs leveraging its proprietary technology platforms.
Looking ahead, Xeris Biopharma remains optimistic about its growth trajectory, with management emphasizing their commitment to strategic execution and sustained momentum across their product portfolio. The company aims to capitalize on its current success to drive further growth and innovation in the biopharmaceutical industry.